References

1. Aron DC, Tyrrell JB, Wilson CB. Pituitary tumors - current concepts in diagnosis and management. West J Med 1995;162:340-352.

2. Katznelson L, Alexander JM, Klibanski A. Clinical Review 45: Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-1094.

3. Young WF, Scheithauer BW, Kovacs KT, Horvath E, David DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc 1996;71:649-656.

4. Ho DM, Hsu CY, Ting LT, Chiang H. The cliniopathological characteristics of gonadotroph cell adenoma: a study of 118 cases. Hum Pathol 1997;28:905-911.

5. Snyder PJ. Gonadotroph cell adenomas of the pituitary. Endocr Rev 1985;6:552-563.

6. Katznelson L, Alexander JM, Bikkal HA, Jameson JL, Hsu DW, Klibanski A. Imbalanced follicle-stimulating hormone ß-subunit hormone biosynthesis in human pituitary adenomas. J Clin Endocrinol Metab 1992;74:1343-1351.

7. Jameson JL, Klibanski A, Black PM, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472-1478.

8. Snyder PJ, Bashey HM, Phillips JL, Gennarelli TA. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture. J Clin Endocrinol Metab 1985;61:1061-1065.

9. Asa SL, Cheng Z, Ramyar L, et al. Human pituitary null cell adenomas and oncocytomas in vitro: effects of adenohypophysiotropic hormones and gonadal steroids on hormone secretion and tumor cell morphology. J Clin Endocrinol Metab 1992;74:1128-1134.

10. Samuels MH, Henry P, Kleinschmidt-DeMasters BK, Lillehei K, Ridgway EC. Pulsatile glycoprotein hormone secretion in glycoprotein-producing pituitary tumors. J Clin Endocrinol Metab 1991;73:1281-1288.

11. Vance ML. Hypopituitarism. N Engl J Med 1994;330:1651-1662.

12. Molitch ME, Russell EJ. The pituitary "incidentaloma." Ann Int Med 1990;112:925-931.

13. Yamada S, Sano T, Stefaneanu L, et al. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 1993;76: 352-356.

14. King JT, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997;82:3625-3632.

15. Lamberts SWJ, deHerder WW, van der Lely AJ, Hofland LJ. Imaging and medical management of clinically nonfunctioning pituitary tumors. Endocrinologist 1995;5:448-450.

16. Hansen LK, Molitch ME. Postoperative radiotherapy for clinically nonfunctioning pituitary adenomas. The Endocrinologist 1998;8:71-78.

17. Guinan EM, Lowy C, Stanhope N, Lewis PD, Kepelman MD. Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatry 1998;65:870-876.

18. Mitsumori M, Shrieve DC, Alexander E, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 1998;42:573-580.

19. Laws ER, Vance ML. Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin North Am 1999;10:327-336.

20. Izawa M, Hayashi M, Nakaya K, et al. Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 2000;93 (Suppl 3):19-22.

21. Colao A, Ferone D, Lastoria S, et al. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol 2000;52:437-445.

22. Giusti M, Bocca L, Glorio T, et al. Cabergoline modulation of a-subunit and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest 2000;23:463-466.

23. Nobels FR, de Herder WW, van den Brink WM, et al. Long-term treatment with the dopamine agonist quinagolide of patients with clinically nonfunctioning pituitary adenoma. Eur J Endocrinol 2000;143:615-621.

24. Plockinger U, Reichel M, Fett U, Seager W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994;79:1416-1423.

25. Warnet A, Harris AG, Renard E, Martin D, James-Deidier A, Chaumet-Riffaud P. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997;41:786-795.

26. Andersen M, Bjerre P, Schroder HD, et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically nonfunctioning pituitary adenomas. Clin Endocrinol 2001;54:23-30.

27. Roman SH, Goldstein M, Kourides IA, et al. The luteinizing hormone-releasing hormone (LHRH) agonist (D-trp6-pro9-NEt) LHRH increased rather than lowered LH and a-subunit levels in a patient with an LH-secreting pituitary tumor. J Clin Endocrinol Metab 1984;58: 313-319.

28. Sassolas G, LeJeune H, Trouillas J, et al. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1988;67:180-185.

29. Zarate A, Fonseca ME, Mason M, et al. Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist. Acta Endocrinol 1986;113:29-34.

30. Chapman AJ, MacFarlane IA, Shalet SM, et al. Discordant serum a-subunit and FSH concentrations in a woman with a pituitary tumor. Clin Endocrinol 1984;21:123-129.

31. Klibanski A, Jameson JL, Biller BMK, et al. Gonadotropin and a-subunit responses to chronic LHRH analogue administration in patients with pituitary tumors. J Clin Endocrinol Metab 1989;68:81-86.

32. McGrath GA, Goncalves RJ, Udupa JK, et al. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1993;76:1363-1368.

33. Rodriguez O, Mateos B, de la Pedraja R, et al. Postoperative follow-up of pituitary adenomas after transsphenoidal resection: MRI and clinical correlation. Neuroradiology 1996;38: 747-754.

34. Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1986;62:1173-1179.

35. Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 1999;84: 3696-3700.

36. Abdu TA, Elhadd TA, Neary R, Clayton RN. Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg) and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 1999;84:838-843.

37. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999;341:1206-1216.

38. Ho KK. Diagnosis and management of adult growth hormone deficiency. Endocrine 2000;12:189-196.

39. Biller BMK, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067-2079.

40. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457-462.

41. Tominaga A, Uozumi T, Arita K, Kurisu K, Yano T, Hirohata T. Anterior pituitary function in patients with nonfunctioning pituitary adenoma: results of longitudinal follow-up. Endocr J 1995;42:421-427.

Was this article helpful?

0 0

Post a comment